LungBlog

The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Non-Small Cell Lung Cancer (NSCLC) Guidelines. The NCCN Clinical Practice Guidelines in Oncology™ are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings.

A congressional committee is asking the National Cancer Institute to scrutinize the financial records of about 50 researchers leading a big government study of whether annual medical scans of smokers’ lungs can save lives.

Researchers from the UK have reported that the addition of Thalomid to etoposide plus Paraplatin (carboplatin) did not improve outcomes of patients with advanced small cell lung cancer SCLC). The details of this randomized trial were presented at the Presidential Symposium of the 12th World Conference on Lung Cancer in Seoul, Korea, September 2-6, 2007.

OSI Pharmaceuticals Inc. said Monday its lung cancer drug Tarceva received regulatory approvals in Japan.

Porter Wagoner has lung cancer and remains hospitalized in serious condition, a publicist for the country singer said Saturday

Friends and co-workers of Boulder County sheriff’s Sgt. Peggy Driscoll, a 27-year veteran of the office, will host a benefit dinner Wednesday to help offset the medical costs of Driscoll’s battle with lung cancer

Radon, an odorless, tasteless, invisible and naturally occurring gas, has become the second leading cause of lung cancer, according to the U.S. Environmental Protection Agency. The radioactive gas gets into the air and, when taken into the lungs, causes disease, the EPA said.

Cell Therapeutics, Inc. (CTI)  will sponsor a conference entitled “Women, Smoke and Lung Cancer” in Milan on Wednesday, October 24. The conference, organized by the National Observatory of Women’s Health (O.N.Da), will inform women about the dangers and consequences of smoking, provide an update on lung cancer research, and the importance of prevention and early detection as well as advancements in the treatment of the disease.

Biopharmaceutical company Poniard Pharmaceuticals Inc. Wednesday said its prospective lung cancer treatment received orphan drug status from the European Commission.

Pharmion Corporation today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company’s third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.